- Home
- EQ vs PLRX Comparison
EQ vs PLRX Comparison
Compare EQ & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQ
- PLRX
- Stock Information
- Founded
- EQ 2017
- PLRX 2015
- Country
- EQ United States
- PLRX United States
- Employees
- EQ N/A
- PLRX N/A
- Industry
- EQ Biotechnology: Pharmaceutical Preparations
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- EQ Health Care
- PLRX Health Care
- Exchange
- EQ Nasdaq
- PLRX Nasdaq
- Market Cap
- EQ 85.1M
- PLRX 93.3M
- IPO Year
- EQ 2018
- PLRX 2020
- Fundamental
- Price
- EQ $1.39
- PLRX $1.63
- Analyst Decision
- EQ Hold
- PLRX Hold
- Analyst Count
- EQ 2
- PLRX 11
- Target Price
- EQ $1.00
- PLRX $3.93
- AVG Volume (30 Days)
- EQ 489.3K
- PLRX 1.0M
- Earning Date
- EQ 11-11-2025
- PLRX 11-07-2025
- Dividend Yield
- EQ N/A
- PLRX N/A
- EPS Growth
- EQ N/A
- PLRX N/A
- EPS
- EQ N/A
- PLRX N/A
- Revenue
- EQ $16,553,000.00
- PLRX N/A
- Revenue This Year
- EQ N/A
- PLRX N/A
- Revenue Next Year
- EQ N/A
- PLRX N/A
- P/E Ratio
- EQ N/A
- PLRX N/A
- Revenue Growth
- EQ N/A
- PLRX N/A
- 52 Week Low
- EQ $0.27
- PLRX $1.10
- 52 Week High
- EQ $2.35
- PLRX $16.10
- Technical
- Relative Strength Index (RSI)
- EQ 48.48
- PLRX 48.87
- Support Level
- EQ $1.31
- PLRX $1.61
- Resistance Level
- EQ $1.58
- PLRX $1.95
- Average True Range (ATR)
- EQ 0.13
- PLRX 0.13
- MACD
- EQ 0.01
- PLRX -0.02
- Stochastic Oscillator
- EQ 48.64
- PLRX 18.75
About EQ Equillium Inc.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.